PharVision Advisers’s Scansource SCSC Stock Holding History

PharVision Advisers’s Portfolio SCSC Stock Details SCSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,904	Closed	-$371K	–	411
2025 Q1	$371K	Buy	+10,904	New	+$445K	0.51%	56

Other funds holding SCSC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pzena Investment Management New York $30.8B AUM 11.29% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PharVision Advisers's SCSC Position: Q2 2025 in Review

PharVision Advisers sold out of Scansource (SCSC) in Q2 2025, closing a stake of 10,904 shares — an estimated $371K sold.

PharVision Advisers first reported a position in SCSC in Q1 2025 and held it in 1 quarter. The position peaked at $371K in Q1 2025. 206 funds tracked by Wall St. Rank hold SCSC as of Q2 2025.

PharVision Advisers reported no remaining Scansource position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 10,904 Scansource shares in Q2 2025, an estimated $371K.
PharVision Advisers first reported a position in Scansource in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Scansource position peaked at $371K in Q1 2025.
206 funds tracked by Wall St. Rank held Scansource as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.